{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:02:51Z","timestamp":1777377771607,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      In somatostatin receptor (SSTR)-expressing tumors, theranostics with SSTR-directed imaging and therapy showed promising results regarding disease control. This study evaluated the use of PET imaging with [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE in pheochromocytoma and paraganglioma (PPGL) patients, focusing on eligibility for peptide radioreceptor therapy (PRRT) and therapy monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Five patients with metastatic paraganglioma (n\u2009=\u20093) or pheochromocytoma (n\u2009=\u20092) were included. Eligibility for PRRT was assessed by [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE applying the Krenning score and baseline SUV\n                      <jats:sub>max<\/jats:sub>\n                      . Treatment response was analyzed by RECIST 1.1 criteria, total tumor volume (PET-based TTV), and Chromogranin A (CgA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUV\n                      <jats:sub>max<\/jats:sub>\n                      41.4\u2009\u00b1\u200987.3) and a high Krenning Score of 3\u20134, Suggestive for PRRT eligibility. At the follow up, 2.5 months after completion of PRRT, all patients presented with stable disease (RECIST 1.1) and decreasing or stable CgA levels, whereas TTV increased in three patients and thus showed heterogenous response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In metastatic PPGL, [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE effectively visualizes tumor burden and supports patient selection and response assessment for PRRT. Notably, the data revealed a heterogenous response across PET-based, CT-based, and biochemical assessments. The underlying mechanisms of these discrepancies remain unclear and warrant further investigation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07550-2","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:01:07Z","timestamp":1758265267000},"page":"1671-1678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["[18F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paraganglia"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3175-952X","authenticated-orcid":false,"given":"Sophie C.","family":"Siegmund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera U.","family":"Wenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Scheifele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz Josef","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias K.","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lottspeich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kroi\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"V\u00f6lter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Auernhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"3","key":"7550_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2478\/enr-2019-0020","volume":"53","author":"FA Farrugia","year":"2019","unstructured":"Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul. 2019;53(3):191\u2013212.","journal-title":"Endocr Regul"},{"key":"7550_CR2","first-page":"81","volume":"10","author":"R Lioyd","year":"2017","unstructured":"Lioyd R, et al. WHO classification of tumours of endocrine organs. WHO Classif Tumours. 2017;10:81\u201391.","journal-title":"WHO Classif Tumours"},{"issue":"6","key":"7550_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","volume":"39","author":"H Chen","year":"2010","unstructured":"Chen H, et al. The North American neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775\u201383.","journal-title":"Pancreas"},{"issue":"4","key":"7550_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00432-020-03138-5","volume":"146","author":"I Jochmanova","year":"2020","unstructured":"Jochmanova I, et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol. 2020;146(4):1051\u201363.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"7550_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00005792-199101000-00003","volume":"70","author":"RJ Hsiao","year":"1991","unstructured":"Hsiao RJ, et al. Chromogranin a storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore). 1991;70(1):33\u201345.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"7550_CR6","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1007\/s00259-019-04448-8","volume":"46","author":"H Ilhan","year":"2019","unstructured":"Ilhan H, et al. First-in-human (18)F-SiFAlin-TATE PET\/CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging. 2019;46(11):2400\u20131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7550_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7550_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s00259-024-06944-y","volume":"52","author":"SC Kunte","year":"2025","unstructured":"Kunte SC, et al. PET\/ct imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [(18)F]SiTATE - first clinical experiences. Eur J Nucl Med Mol Imaging. 2025;52(3):900\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7550_CR9","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","volume":"50","author":"M Unterrainer","year":"2023","unstructured":"Unterrainer M, et al. Next-generation PET\/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE. Eur J Nucl Med Mol Imaging. 2023;50(11):3390\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7550_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","volume":"86","author":"H Leijon","year":"2019","unstructured":"Leijon H, et al. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol. 2019;86:66\u201375.","journal-title":"Hum Pathol"},{"key":"7550_CR11","doi-asserted-by":"crossref","unstructured":"Hertelendi M et al. Efficacy and safety of [(177)Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin Receptor-Positive pheochromocytomas\/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma: a systematic literature review. Biomedicines, 2023. 11(4).","DOI":"10.3390\/biomedicines11041024"},{"issue":"1","key":"7550_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0044-1791819","volume":"24","author":"Y Edamadaka","year":"2025","unstructured":"Edamadaka Y, et al. Metastatic malignant paraganglioma of rare sites failed on conventional treatments demonstrating beneficial response to (177) Lu-DOTATATE PRRT. World J Nucl Med. 2025;24(1):83\u201392.","journal-title":"World J Nucl Med"},{"key":"7550_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.957172","volume":"13","author":"S Prado-Wohlwend","year":"2022","unstructured":"Prado-Wohlwend S, et al. Response to targeted radionuclide therapy with [(131)I]MIBG AND [(177)Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: a systematic review. Front Endocrinol (Lausanne). 2022;13:957172.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"7550_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100171","volume":"6","author":"S Severi","year":"2021","unstructured":"Severi S, et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open. 2021;6(4):100171.","journal-title":"ESMO Open"},{"issue":"12","key":"7550_CR15","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1038\/s41596-020-00407-y","volume":"15","author":"S Lindner","year":"2020","unstructured":"Lindner S, et al. Radiosynthesis of [(18)F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Nat Protoc. 2020;15(12):3827\u201343.","journal-title":"Nat Protoc"},{"key":"7550_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","volume":"88\u201389","author":"S Lindner","year":"2020","unstructured":"Lindner S, et al. Automated production of [(18)F]SiTATE on a scintomics GRP\u2122 platform for PET\/CT imaging of neuroendocrine tumors. Nucl Med Biol. 2020;88\u201389:86\u201395.","journal-title":"Nucl Med Biol"},{"key":"7550_CR17","doi-asserted-by":"crossref","unstructured":"Urso L et al. Lutathera(\u00ae) Orphans: State of the Art and Future Application of Radioligand Therapy with (177)Lu-DOTATATE. Pharmaceutics, 2023. 15(4).","DOI":"10.3390\/pharmaceutics15041110"},{"key":"7550_CR18","unstructured":"Novartis. Fachinformation Lutathera. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200401147483\/anx_147483_de.pdf"},{"key":"7550_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"Ambrosini V, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56\u201373.","journal-title":"Eur J Cancer"},{"issue":"8","key":"7550_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/RLU.0000000000004239","volume":"47","author":"A Weich","year":"2022","unstructured":"Weich A, et al. Rechallenge with additional doses of 177Lu-DOTATOC after failure of maintenance therapy with cold somatostatin analogs. Clin Nucl Med. 2022;47(8):719\u201320.","journal-title":"Clin Nucl Med"},{"issue":"Suppl 2","key":"7550_CR21","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","volume":"10","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(Suppl 2):S23\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"7550_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","volume":"45","author":"AK Seitz","year":"2018","unstructured":"Seitz AK, et al. Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45(4):602\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7550_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"7550_CR24","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1038\/s41598-025-88999-x","volume":"15","author":"A Hinterberger","year":"2025","unstructured":"Hinterberger A, et al. Structured reporting of neuroendocrine tumors in PET\/CT using [18F]SiTATE - impact on interdisciplinary communication. Sci Rep. 2025;15(1):4793.","journal-title":"Sci Rep"},{"issue":"11","key":"7550_CR25","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00259-021-05351-x","volume":"48","author":"L Beyer","year":"2021","unstructured":"Beyer L, et al. Dosimetry and optimal scan time of [(18)F]SiTATE-PET\/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2021;48(11):3571\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7550_CR26","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013;98(4):1492\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7550_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1677\/ERC-07-0074","volume":"14","author":"A Chrisoulidou","year":"2007","unstructured":"Chrisoulidou A, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14(3):569\u201385.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"7550_CR28","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","volume":"108","author":"A Fischer","year":"2023","unstructured":"Fischer A, et al. Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses. J Clin Endocrinol Metab. 2023;108(10):2676\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"7550_CR29","doi-asserted-by":"publisher","first-page":"929391","DOI":"10.3389\/fendo.2022.929391","volume":"13","author":"M Opali\u0144ska","year":"2022","unstructured":"Opali\u0144ska M, et al. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET\/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol (Lausanne). 2022;13:929391.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"7550_CR30","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/jc.2017-00816","volume":"102","author":"G Kong","year":"2017","unstructured":"Kong G, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab. 2017;102(9):3278\u201387.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"7550_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma DA, et al. Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):623\u201330.","journal-title":"J Nucl Med"},{"issue":"1","key":"7550_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/nyas.14249","volume":"1455","author":"SK Mahata","year":"2019","unstructured":"Mahata SK, Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci. 2019;1455(1):34\u201358.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"7550_CR33","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/bjc.1998.635","volume":"78","author":"E Baudin","year":"1998","unstructured":"Baudin E, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998;78(8):1102\u20137.","journal-title":"Br J Cancer"},{"issue":"4","key":"7550_CR34","first-page":"384","volume":"61","author":"P Glinicki","year":"2010","unstructured":"Glinicki P, Jeske W. Chromogranin A (CgA)--the influence of various factors in vivo and in vitro, and existing disorders on it\u2019s concentration in blood. Endokrynol Pol. 2010;61(4):384\u20137.","journal-title":"Endokrynol Pol"},{"issue":"2","key":"7550_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cen.14585","volume":"96","author":"L Liu","year":"2022","unstructured":"Liu L, et al. Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: which is the best diagnostic strategy. Clin Endocrinol (Oxf). 2022;96(2):132\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"7550_CR36","doi-asserted-by":"publisher","first-page":"e13349","DOI":"10.1111\/jne.13349","volume":"35","author":"CYL Tang","year":"2023","unstructured":"Tang CYL, et al. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: a single-institution experience and review of the literature. J Neuroendocrinol. 2023;35(12):e13349.","journal-title":"J Neuroendocrinol"},{"key":"7550_CR37","doi-asserted-by":"publisher","first-page":"1141648","DOI":"10.3389\/fonc.2023.1141648","volume":"13","author":"D Su","year":"2023","unstructured":"Su D, et al. Peptide receptor radionuclide therapy in advanced pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Front Oncol. 2023;13:1141648.","journal-title":"Front Oncol"},{"key":"7550_CR38","doi-asserted-by":"crossref","unstructured":"Vyakaranam AR et al. Favorable outcome in patients with pheochromocytoma and paraganglioma treated with (177)Lu-DOTATATE. Cancers (Basel), 2019. 11(7).","DOI":"10.3390\/cancers11070909"},{"key":"7550_CR39","doi-asserted-by":"crossref","unstructured":"Kolasinska-\u0106wik\u0142a A et al. A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. J Clin Med, 2019. 8(7).","DOI":"10.3390\/jcm8070952"},{"issue":"Suppl 2","key":"7550_CR40","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, et al. Scintigraphy and radionuclide therapy with indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1-octreotide. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S219\u201323.","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"10","key":"7550_CR41","doi-asserted-by":"publisher","first-page":"e05267","DOI":"10.1016\/j.heliyon.2020.e05267","volume":"6","author":"M Tamal","year":"2020","unstructured":"Tamal M. Intensity threshold based solid tumour segmentation method for positron emission tomography (PET) images: a review. Heliyon. 2020;6(10):e05267.","journal-title":"Heliyon"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07550-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07550-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07550-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:34Z","timestamp":1769834614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07550-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7550"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07550-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis was performed in compliance with the principles of the Declaration of Helsinki and was approved by the institutional ethics committee of the Ludwig-Maximilians-University of Munich (IRB #21\u20130102 and #24\u20130982).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AH: Personal fees from ABX advanced biochemical compounds. RAW: speaker honoraria from Novartis\/AAA and PentixaPharm, advisory board work for Novartis\/AAA and Bayer. MJZ: speaker honoraria from Novartis, SIRTEX and Terumo, advisory board for Boston Scientific. MKA: speaker honoria from AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}